Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia DiagnosticsCarmen Alonso, Eva Barragán, Marta Llop et al.|Journal of Molecular Diagnostics|2018Cited by 33
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA RegistryClaudia Sargas, Blanca Boluda, Cristina Gil et al.|Cancers|2023Cited by 30
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupClaudia Sargas, Rosa Ayala, María José Larráyoz et al.|Blood Cancer Journal|2023Cited by 28
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimensTamara Castaño-Bonilla, Pau Montesinos, Juan Manuel Alonso‐Domínguez et al.|Scientific Reports|2021Cited by 25
S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AMLPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|HemaSphere|2023Cited by 14